Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
18.06
27.61
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co Ltd
Income from Continuing Operations
Hunan Jiudian Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
|
Income from Continuing Operations
¥508m
|
CAGR 3-Years
37%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income from Continuing Operations
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Income from Continuing Operations
¥3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income from Continuing Operations
¥5.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income from Continuing Operations
¥4.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Income from Continuing Operations
-¥780.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hunan Jiudian Pharmaceutical Co Ltd
Glance View
Hunan Jiudian Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products. The company is headquartered in Changsha, Hunan and currently employs 1,450 full-time employees. The company went IPO on 2017-10-10. The Company’s products are comprised of pharmaceutical preparations, raw materials, pharmaceutical excipients and plant extracts, including loxoprofen sodium gel ointment, ornidazole raw materials and preparations, dirithromycin raw materials and preparations, clindamycin phosphate tablets and so on. The products are used for the treatment of bacterial infections and anti-allergy. The firm sells its products to both domestic and international markets, including Europe, South Korea, India, Russia and South America.
See Also
What is Hunan Jiudian Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
508m
CNY
Based on the financial report for Sep 30, 2024, Hunan Jiudian Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 508m CNY.
What is Hunan Jiudian Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
51%
Over the last year, the Income from Continuing Operations growth was 37%. The average annual Income from Continuing Operations growth rates for Hunan Jiudian Pharmaceutical Co Ltd have been 37% over the past three years , 51% over the past five years .
You don't have any saved screeners yet
